Velit Biologics

Velit Biologics develops SB101, an angiogenesis inhibitor for post-VEGF treatment.

  • Stage Prototype Ready
  • Industry Healthcare Services
  • Location Seminariegatan, Gothenburg, Sweden
  • Currency SEK
  • Founded May 2011
  • Employees 9
  • Website velitbiologics.com

Company Summary

Velit Biologics is a pre-company (not incorporated) with a Project Board represented by Encubator AB and Celecure AS. The structure defines ownership, responsibilities and IP. The projects purpose is to progress the commercial development of SB101.

Team

  • Alexander Lagerman
    Project Manager

    Entrepreneurial background in bioscience and drug development in particular.

  • Tarmo Kivi
    Chairman

    Founder & CEO of Celecure AS. Has participated in several entrepreneurial projects and former investment specialist at SEAF.

  • Andres Valkna
    Chief Science Officer

    Vice Professor in Molecular Biology at Tallin Technical University. Leading researcher at Competence Centre for Cancer Research

  • Mattias Münnich
    Board Member

    Director Business Operations at Pergamum.
    - Partnering and licensing activities for projects in clinical development phase.
    - Contract negotiation with subcontractors, development partners and hospitals.
    - Sponsor contact towards Principle Investigators and clinical trial sites.

  • Alexander Lagerman

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free